Geode Capital Management, LLC Geron Corp Transaction History

Geode Capital Management, LLC

$1.21 Trillion
Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Geron Corp stock. As of the latest transaction made, Geode Capital Management, LLC holds 13,067,999 shares of GERN stock, worth $52.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,067,999

Previous 12,836,821 1.8%

Holding current value

$52.8 Million

Previous $54.4 Million 9.0%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$4.17 - $4.99 $964,012 - $1.15 Million	231,178 Added 1.8%	13,067,999 $59.3 Million
Q2 2024 Aug 09, 2024	BUY	$3.1 - $5.09 $4.37 Million - $7.18 Million	1,410,836 Added 12.35%	12,836,821 $54.4 Million
Q1 2024 May 13, 2024	BUY	$1.75 - $3.44 $844,088 - $1.66 Million	482,336 Added 4.41%	11,425,985 $37.7 Million
Q4 2023 Feb 13, 2024	BUY	$1.74 - $2.31 $1.62 Million - $2.15 Million	930,747 Added 9.3%	10,943,649 $23.1 Million
Q3 2023 Nov 13, 2023	BUY	$2.11 - $3.28 $1.47 Million - $2.29 Million	697,504 Added 7.49%	10,012,902 $21.2 Million
Q2 2023 Aug 11, 2023	BUY	$1.97 - $3.69 $2.43 Million - $4.55 Million	1,233,548 Added 15.26%	9,315,398 $29.9 Million
Q1 2023 May 15, 2023	BUY	$2.14 - $3.4 $3.54 Million - $5.63 Million	1,655,765 Added 25.77%	8,081,850 $17.5 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $505,626 - $602,766	249,077 Added 4.03%	6,426,085 $15.6 Million
Q3 2022 Nov 14, 2022	SELL	$1.67 - $2.94 $258,664 - $455,373	-154,889 Reduced 2.45%	6,177,008 $14.5 Million
Q2 2022 Aug 12, 2022	BUY	$1.19 - $1.65 $710,225 - $984,766	596,828 Added 10.41%	6,331,897 $9.81 Million
Q1 2022 May 13, 2022	BUY	$0.99 - $1.6 $261,805 - $423,120	264,450 Added 4.83%	5,735,069 $7.8 Million
Q4 2021 Feb 11, 2022	SELL	$1.22 - $1.72 $147,207 - $207,538	-120,662 Reduced 2.16%	5,470,619 $6.67 Million
Q3 2021 Nov 12, 2021	BUY	$1.2 - $1.5 $496,792 - $620,991	413,994 Added 8.0%	5,591,281 $7.66 Million
Q2 2021 Aug 13, 2021	BUY	$1.25 - $1.83 $395,877 - $579,564	316,702 Added 6.52%	5,177,287 $7.3 Million
Q1 2021 May 12, 2021	BUY	$1.52 - $2.1 $459,178 - $634,391	302,091 Added 6.63%	4,860,585 $7.68 Million
Q4 2020 Feb 12, 2021	BUY	$1.55 - $2.05 $17,243 - $22,806	11,125 Added 0.24%	4,558,494 $7.25 Million
Q3 2020 Nov 13, 2020	BUY	$1.59 - $2.19 $847,889 - $1.17 Million	533,264 Added 13.28%	4,547,369 $7.91 Million
Q2 2020 Aug 13, 2020	BUY	$1.05 - $2.18 $1.34 Million - $2.78 Million	1,276,849 Added 46.65%	4,014,105 $8.75 Million
Q1 2020 May 14, 2020	BUY	$0.89 - $1.49 $234,384 - $392,395	263,353 Added 10.65%	2,737,256 $3.26 Million
Q4 2019 Feb 13, 2020	BUY	$1.27 - $1.54 $149,127 - $180,831	117,423 Added 4.98%	2,473,903 $3.36 Million
Q3 2019 Nov 12, 2019	BUY	$1.15 - $1.59 $6,120 - $8,461	5,322 Added 0.23%	2,356,480 $3.13 Million
Q2 2019 Aug 14, 2019	BUY	$1.37 - $2.02 $224,129 - $330,467	163,598 Added 7.48%	2,351,158 $3.32 Million
Q1 2019 May 14, 2019	BUY	$1.01 - $1.83 $297,954 - $539,857	295,004 Added 15.59%	2,187,560 $3.63 Million
Q4 2018 Feb 13, 2019	BUY	$0.98 - $1.85 $74,612 - $140,849	76,135 Added 4.19%	1,892,556 $1.89 Million
Q3 2018 Nov 13, 2018	BUY	$1.76 - $6.38 $371,914 - $1.35 Million	211,315 Added 13.17%	1,816,421 $3.2 Million
Q2 2018 Aug 14, 2018	BUY	$3.29 - $4.82 $548,436 - $803,484	166,698 Added 11.59%	1,605,106 $5.51 Million
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $169,506 - $560,027	93,650 Added 6.96%	1,438,408 $6.11 Million
Q4 2017 Feb 13, 2018	BUY	$1.8 - $2.32 $45,104 - $58,134	25,058 Added 1.9%	1,344,758 $2.42 Million
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $39,969 - $53,225	20,085 Added 1.55%	1,319,700 $2.88 Million
Q2 2017 Aug 14, 2017	BUY	N/A	1,299,615	1,299,615 $3.6 Million

Others Institutions Holding GERN

# of Institutions

275

Shares Held

491M

Call Options Held

1.87M

Put Options Held

690K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.53B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Geron Corp Transaction History